Fitz Respiratory PACES Notes

Total Page:16

File Type:pdf, Size:1020Kb

Fitz Respiratory PACES Notes Respiratory 1. Interstitial lung disease (most frequent by a long way!) 2. Bronchiectasis 3. Cystic fibrosis 4. Pneumonectomy/lobectomy 5. Pleural effusion 6. Chronic obstructive airways disease 7. SVC obstruction 8. Cor pulmonale 9. Apical fibrosis Oral presentation • Tachypnoeic? • Peripheral signs • Key findings • Consistent with …DD • Is there evidence of… o Asterixis? o Cor pulmonale? o Infective exacerbation Interstitial lung disease History: • Dry cough • SoB esp on exertion • Leg swelling • Occupational Hx • Hobbies • Drugs now, in past Examination • Clubbing • Signs of steroid use • Central cyanosis • Decreased symmetrical chest expansion • Bilateral fine end inspiratory crackles Pulmonary hypertension – a wave with raised JVP, Left parasternal heave, loud P2 What are the causes of lung fibrosis? • Idiopathic pulmonary fibrosis (aka CFA, or histological diagnosis of UIP) o Hamman-Rich syndrome is an aggressive fatal from of interstitial pneumonitis in young, otherwise well patients with little obvious cause. Rx supportive. • Connective tissue diseases o Rheumatoid lung – hands, nodules o SLE – facies o Systemic sclerosis – facies and hands o Polymyositis – prox muscle weakness or tenderness o Dermatomyositis – heliotrope rash and gottron’s papules o Sjorgren’s syndrome o MCTD o Ankylosing spondylitis - posture • Drugs – many o Anti-cancer: esp Methotrexate, Cyclophosphamide, busulfan, bleomycin o Anti-arrhythmics: Amiodarone o Anti-inflammatory: Sulfasalazine, gold o Anti-biotics: Nitrofurantion, sulphonamides • Radiotherapy – scars, localised, tattoos • Pneumoconioses o Asbestosis o Coal workers’ pneumoconiosis o Silicosis (silica) o Beryliosis – Beryllium (lightbulbs) o Byssinosis – cotton o Chalicosis – stone o Bauxite fibrosis o Baritosis – Barium – generally benign with striking CXR abnormalities • Sarcoidosis • Extrinsic allergic alveolitis o Alveolar inflammation due to hypersensitivity to inhaled organic particles (Type III and IV hypersensitivity) o Bird fancier’s lung o Cheese washer’s lung o Farmer’s lung o Hot tub lung o Malt worker’s lung o Miller’s lung o Wood worker’s lung How would you investigate a patient with fibrosis? • ABG – hypoxia • CXR – reticulonodular shadowing and honeycombing • Bloods incl. ESR, RF, ANA, Igs • Formal spirometry with a restrictive pattern and decreased gas transfer • HRCT Treatment? • MDT – PT, OT, SW, CNS • Oxygen, treatment of infections early • NIV if indicated • No Dx modifying Rx for IPF – palliate • Reduce exposure to cause • Steroids/Aza, Cyclophosphamide • Rarely single Lung transplant • Inform about occupational health compensation Causes of pulmonary fibrosis by zone Upper zone • Ank spond • Carconoma • EAA • Pneumoconiosis (except Asbestosis) • TB Middle zone • Sarcoid Lower zone • Asbestosis • IPF/CFA • RA/SLE Generalised • Chemotherapy Anywhere • Radiotherapy Pleural effusion What are the causes? • Transudates? o CCF o Hypoalbuminaemia o Renal failure o Hypothyroidism o Meig’s syndrome – right sided pleural effusion with ovarian mass • Exudate? o Malignancy . Primary . Secondary o Infection . Parapneumonic . Empyema . TB o Inflammatory . Rheumatoid . SLE o PE How do you distinguish between a transudate or an exudates? • Classically ><30g/L • However Light’s criteria more accurate o Effusion/Serum protein >50% o Effusion/Serum LDH >60% o Effusion LDH > 2/3 normal range Pneumonectomy Examination • Deformity of chest • Flattening of lateral side • Thoracotomy scar • Tracheal deviation to that side • Decreased expansion on that side • No AE in bases • Bronchial breathing in upper zones (Lobectomy As above but central trachea, and diminuished AE and percussion note. ) Indications for lung resection • NSC Lung Ca • Solitary pulmonary nodules of uncertain cause • Bronchiectasis – localised • Massive haemoptysis from bronchiectasis or benign or malignant lesion • TB treatment in pre-antibiotic era Thoracoplasty Rib removal Less dull, more AE If with bronchiectasis or upper lobe signs - ?old TB What are the types of lung cancer? What are the treatment options for lung cancer? How do you diagnose and manage TB? What are the causes of haemoptysis? How would you manage haemoptysis? Bronchiectasis Permanent pathological dilatation of distal airways with chronic infection Hx • SoB • Cough productive of purulent sputum • Infections • DM, diarrhoea, wt loss – CF • Sinusitis – Kartagener’s • Inflammatory disorder • Hx childhood infections Examination • Thin • High RR • Cyanosis • Clubbing • Sputum pot with purulent sputum • Hyperexpanded chest • Coarse late insp and exp crackles with clicks and wheezes DD of clubbing and crackles • Fibrosing alveolitis (but no clicks, wheeze or sputum) • Bronchial Ca with infection • Lung abscess Causes • Congenital o Primary ciliary dyskinesia o Kartagener’s syndrome (as above with sinusitis, bronchiectasis, situs inversus and infertility) o Anatomical defects • Cystic fibrosis • Bronchial obstruction from foreign body, Cancer, granuloma, LNs • Childhood respiratory infections – esp Pertussis, measles, mycoplasma • ABPA • Hypogammaglobulinaemia • Yellow-nail syndrome • Chronic aspiration • Inflammatory disorders o RA, SLE, Sjogren’s, Marfans Investigations • Sputum MCS • CXR – tramlines, ring shadows • HRCT • A1AT • Aspergillus skin prick test for ABPA • RF or CCP in RA • HIV • Sweat chloride test for CF • Exhaled NO for ciliary disorders Treatment • PT • Abx – oral or nebulised • Bronchodilators • Surgery Findings on Pulm function tests? • Reduced FVC and FEV1 with a reduced FEV1/FVC > 70%. Cystic fibrosis History: • Recurrent chest infections since childhood • Productive cough with sputum • SOBOE • Symptoms of malabsorption with diarrhoea, short statue and under-weight • Symptoms of diabetes Examination: On observation • Short statue/ thin • Oxygen – wall/concentrator • Nebuliser/ NIV • Antibiotics, mucolytics • Insulin needles or BM equipment • ?Portacath/hickman line • ?PEG Gross Clubbing of fingers and toes (maybe insulin testing marks) • Lines/ scars from neck lines • Reduced expansion • Bilateral coarse crackles with pops, clicks and wheeze consistent with bronchiectasis • Possible Cor pulmonale What is cystic fibrosis? What are the major medical complications of cystic fibrosis? What is the management of cystic fibrosis? • Education o Patient, partner, family o Genetic testing • RFs o smoking o contact with MDR organisms • MDT o Dietitian – supplements/ feed o PT – postural drainage o OT – home modifications o CNS – Chest and DM o Drs – Chest, Endocrine, Gastro o Transplant coordinators • Medical o Bronchodilators and mucolytics o ABx – PO, IV, Nebs o Oxygen/NIV o Supplemental nutrition and creon o Diabetes care with insulin and .
Recommended publications
  • Ep001476158b1*
    (19) *EP001476158B1* (11) EP 1 476 158 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/455 (2006.01) A61P 29/00 (2006.01) 14.11.2007 Bulletin 2007/46 A61P 11/00 (2006.01) C07D 405/12 (2006.01) C07D 213/82 (2006.01) C07D 401/12 (2006.01) (2006.01) (21) Application number: 03739392.3 C07D 451/04 (22) Date of filing: 03.02.2003 (86) International application number: PCT/IB2003/000439 (87) International publication number: WO 2003/068235 (21.08.2003 Gazette 2003/34) (54) NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS NICOTINAMID-DERIVATE ALS PDE4-HEMMER DERIVES DE NICOTINAMIDE UTILES COMME INHIBITEURS DE PDE4 (84) Designated Contracting States: • HENDERSON, A.J., AT BE BG CH CY CZ DE DK EE ES FI FR GB GR c/o UK Patent Dept., HU IE IT LI LU MC NL PT SE SI SK TR Pfizer Ltd. Designated Extension States: Sandwich, Kent CT13 9NJ (GB) AL LT LV MK RO • MAGEE, T.V., c/o Pfizer Global Res. and Develop. (30) Priority: 11.02.2002 GB 0203196 Groton, CT 06340 (US) 10.09.2002 GB 0220999 • MARFAT, A., 21.10.2002 GB 0224453 c/o Pfizer Global Res. and Develop. 20.11.2002 GB 0227139 Groton, CT 06340 (US) • MATHIAS, J.P., (43) Date of publication of application: c/o Pfizer Global Res. and Develop. 17.11.2004 Bulletin 2004/47 Sandwich, Kent CT13 9NJ (GB) (73) Proprietors: • MCLEOD, D.G., • Pfizer Limited c/o Pfizer Global Res.
    [Show full text]
  • MS32-Chun-Red
    Text19/12/2008 MATERIAL SAFETY DATA SHEET PRODUCT / MATERIAL: GLAZE MANUFACTURER / DISTRIBUTOR: LAGUNA CLAY COMPANY ADDRESS: 14400 Lomitas Avenue, City of Industry, CA 91746 PHONE / FAX / EMAIL: (626) 330-0631 / (626) 333-7694 / [email protected] SECTION I - PRODUCT INFORMATION TRADE NAME: MS32 SYNONYM: CHUN RED CHEMICAL FAMILY: Ceramic Blend SECTION II - HAZARDOUS INGREDIENTS Maximum OSHA PEL NIOSH REL ACGIH TLV INGREDIENT NAMEPercent CAS NUMBER TWA: (mg/m3) TWA: (mg/m3) TWA: (mg/m3) Barium or Barium Compounds5 7440-39-3 0.5 0.5 0.5 Calcium Carbonate7 1317-65-3 5 5 10 Lithium Carbonate1 554-13-2 Silica, Crystalline (Quartz)20 14808-60-7 10 mg/m3 / 0.05 0.05 %SiO2 + 2 Silicon Carbide1 409-21-2 15 10 Tin or Tin Compounds2 7440-31-5 2 2 Zinc or Zinc Compounds4 7440-66-6 5 5 5 SECTION III - PHYSICAL DATA BOILING POINT (°F) Not Applicable VAPOR PRESSURE Not Applicable VAPOR DENSITY Not Applicable SOLUBILITY IN WATER Insoluble SPECIFIC GRAVITY 1.7 – 3.7 PERCENT VOLATILE BY WEIGHT 0 EVAPORATION RATE 0 APPEARANCE AND ODOR Color varies between moist and dry state; no odor. SECTION IV - FIRE AND EXPLOSION HAZARD DATA FLASH POINT Not Flammable EXTINGUISHING MEDIA Water UNUSUAL FIRE OR EXPLOSION HAZARDS None SPECIAL FIRE FIGHTING PROCEDURES None SECTION V - REACTIVITY DATA STABILITY FACTOR Product is stable. INCOMPATIBILITY None HAZARDOUS DECOMPOSITION PRODUCTS None. Hazardous polymerization will not occur. CONDITIONS TO AVOID Inhalation of dust. Text10MS32 Text10Page 1 of 3 Text19/12/2008 MATERIAL SAFETY DATA SHEET SECTION VI - HEALTH HAZARD DATA Barium or Barium Compounds Chronic Toxicity: Chronic overexposure may lead to varying degress of paralysis of the extremities.
    [Show full text]
  • An Approach to Interpreting Restrictive Spirometric Pattern Results In
    Med Lav 2016; 107, 6: 419-436 An approach to interpreting restrictive spirometric pattern results in occupational settings Federica Tafuro, Massimo Corradi Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy KEY WORDS Diagnostic algorithm; FEV1; FVC; FEV6; FEV1/FVC; interpretative criteria; lung function testing; occupa- tional exposure PAROLE CHIAVE Algoritmi diagnostici; FEV1; FVC; FEV6; FEV1/FVC; criteri interpretativi; test di funzionalità polmonare; esposizione occupazionale SUMMARY Objectives: The aim of this review is to provide an updated overview of definition, epidemiology, diagnostic algo- rithm and occupational exposures related to abnormal restrictive spirometrical pattern (RSP) in order to improve the correct interpretation of spirometry test results by occupational healthcare providers. Methods: A review of the scien- tific English literature of the last 25 years was carried out with MEDLINE and related keywords [(restricti* AND spirometr*) AND occupational]. The first step analysis covered 40 studies and the second step the reference list. Results are presented in four major aims and subquestions. Results: A spirometrical pattern of reduced VC (Vital Capacity), together with a normal FEV1 (Forced Expiratory Volume in 1 Second)/VC ratio, is suggestive, though not diagnostic of restrictive ventilatory defect (RVD). The prevalence of RSP is high in some studies, comparable to obstructive pat- tern, and could be associated to chronic medical conditions (diabetes, congestive heart failure, obesity, hypertension) as well as to increased risk of mortality and lung cancer. In order to predict true restrictive defect [TLC-(Total Lung Capacity) <LLN (Lower Limit of Normality) gold-standard for diagnosing restrictive lung diseases (RLD)] from spirometrical data, mathematical models have been developed, but more studies in occupational setting are necessary to clarify the accuracy of such approaches in health surveillance programmes.
    [Show full text]
  • Local Coverage Determination for Respiratory Therapy
    Local Coverage Determination (LCD): Respiratory Therapy (Respiratory Care) (L34430) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract Type Contract Number Jurisdiction State(s) Palmetto GBA A and B MAC 10111 - MAC A J - J Alabama Palmetto GBA A and B MAC 10211 - MAC A J - J Georgia Palmetto GBA A and B MAC 10311 - MAC A J - J Tennessee Palmetto GBA A and B and HHH MAC 11201 - MAC A J - M South Carolina Palmetto GBA A and B and HHH MAC 11301 - MAC A J - M Virginia Palmetto GBA A and B and HHH MAC 11401 - MAC A J - M West Virginia Palmetto GBA A and B and HHH MAC 11501 - MAC A J - M North Carolina Back to Top LCD Information Document Information LCD ID Original Effective Date L34430 For services performed on or after 10/01/2015 Original ICD-9 LCD ID Revision Effective Date L31593 For services performed on or after 01/29/2018 Revision Ending Date LCD Title N/A Respiratory Therapy (Respiratory Care) Retirement Date Proposed LCD in Comment Period N/A N/A Notice Period Start Date Source Proposed LCD 08/18/2016 N/A Notice Period End Date AMA CPT / ADA CDT / AHA NUBC Copyright Statement 10/02/2016 CPT only copyright 2002-2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use.
    [Show full text]
  • CT Findings of High-Attenuation Pulmonary Abnormalities
    Insights Imaging (2010) 1:287–292 DOI 10.1007/s13244-010-0039-2 PICTORIAL REVIEW CT findings of high-attenuation pulmonary abnormalities Naim Ceylan & Selen Bayraktaroglu & Recep Savaş & Hudaver Alper Received: 5 June 2010 /Revised: 10 July 2010 /Accepted: 16 August 2010 /Published online: 4 September 2010 # European Society of Radiology 2010 Abstract features and radiological findings can significantly improve Objectives To review the computed tomography (CT) diagnostic accuracy. findings of common and uncommon high-attenuation pulmonary lesions and to present a classification scheme Keywords Computed tomography. Pulmonary of the various entities that can result in high-attenuation abnormalities . High attenuation . Nodules . Reticular pulmonary abnormalities based on the pattern and distribu- pattern . Consolidation . Extraparenchymal lesions tion of findings on CT. Background High-attenuation pulmonary abnormalities can result from the deposition of calcium or, less commonly, Introduction other high-attenuation material such as talc, amiodarone, iron, tin, mercury and barium sulphate. CT is highly High-attenuation pulmonary abnormalities can result from a sensitive in the detection of areas of abnormally high variety of different conditions, including from the deposi- attenuation in the lung parenchyma, airways, mediastinum tion of calcium. Amiodarone pulmonary toxicity may cause and pleura. The cause of the calcifications and other high- high-attenuation pulmonary parenchymal opacities. Multi- attenuation conditions may be determined based on the ple dense nodular opacities are rarely seen in siderosis, location and pattern of the abnormalities within the lung stannosis, talcosis and baritosis, in which iron, tin, talc and parenchyma and knowledge of the associated clinical barium sulfate respectively are deposited in the lungs.
    [Show full text]
  • Nebulizers: Diagnosis Codes – Medicare Advantage Policy Appendix
    UnitedHealthcare® Medicare Advantage Policy Appendix: Applicable Code List Nebulizers: Diagnosis Codes This list of codes applies to the Medicare Advantage Policy Guideline titled Approval Date: September 8, 2021 Nebulizers. Applicable Codes The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. The listing of a code does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply. Diagnosis Code Description For HCPCS Codes A7003, A7004, and E0570 A15.0 Tuberculosis of lung A22.1 Pulmonary anthrax A37.01 Whooping cough due to Bordetella pertussis with pneumonia A37.11 Whooping cough due to Bordetella parapertussis with pneumonia A37.81 Whooping cough due to other Bordetella species with pneumonia A37.91 Whooping cough, unspecified species with pneumonia A48.1 Legionnaires' disease B20 Human immunodeficiency virus [HIV] disease B25.0 Cytomegaloviral pneumonitis B44.0 Invasive pulmonary aspergillosis B59 Pneumocystosis B77.81 Ascariasis pneumonia E84.0 Cystic fibrosis with pulmonary manifestations J09.X1 Influenza due to identified novel influenza A virus with pneumonia J09.X2 Influenza due to identified novel influenza A virus with other
    [Show full text]
  • Toxicological Profile for Barium and Barium Compounds
    TOXICOLOGICAL PROFILE FOR BARIUM AND BARIUM COMPOUNDS U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry August 2007 BARIUM AND BARIUM COMPOUNDS ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. BARIUM AND BARIUM COMPOUNDS iii UPDATE STATEMENT A Toxicological Profile for Barium and Barium Compounds, Draft for Public Comment was released in September 2005. This edition supersedes any previously released draft or final profile. Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology and Environmental Medicine/Applied Toxicology Branch 1600 Clifton Road NE Mailstop F-32 Atlanta, Georgia 30333 BARIUM AND BARIUM COMPOUNDS iv This page is intentionally blank. v FOREWORD This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary. The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.
    [Show full text]
  • Statistical Analysis Plan
    Non-Interventional Study Protocol Study Code << DXXXRXXX >> Version V1.4 Date 14 July 2017 Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO) An observational study evaluating the benefits of early intervention with maintenance therapies to prevent or slow down rapid lung function decline in patients who are at high risk at the time of COPD diagnosis in the combined Optimum Patient Care Research Database and Clinical Practice Research Datalink databases TITLE PAGE Non-Interventional Study Protocol Study Code << DXXXRXXX >> Version 14 July 2017 Date 14 July 2017 TABLE OF CONTENTS PAGE TITLE PAGE ........................................................................................................... 1 TABLE OF CONTENTS ......................................................................................... 2 LIST OF ABBREVIATIONS .................................................................................. 5 RESPONSIBLE PARTIES ...................................................................................... 6 PROTOCOL SYNOPSIS DIAPLO STUDY ........................................................... 7 AMENDMENT HISTORY ................................................................................... 12 MILESTONES ....................................................................................................... 13 1. BACKGROUND AND RATIONALE .................................................................. 14 1.1 Background ...........................................................................................................
    [Show full text]
  • Medicare Approved Six Minute Walk Diagnosis Codes
    MEDICARE APPROVED DIAGNOSIS CODES FOR SIX MINUTE WALK TESTING ICD-10 Codes that Support Medical Necessity Group 1 Codes: ICD-10 CODE DESCRIPTION B44.81 Allergic bronchopulmonary aspergillosis C33 Malignant neoplasm of trachea C34.00 Malignant neoplasm of unspecified main bronchus C34.01 Malignant neoplasm of right main bronchus C34.02 Malignant neoplasm of left main bronchus C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung C34.11 Malignant neoplasm of upper lobe, right bronchus or lung C34.12 Malignant neoplasm of upper lobe, left bronchus or lung C34.2 Malignant neoplasm of middle lobe, bronchus or lung C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung C34.31 Malignant neoplasm of lower lobe, right bronchus or lung C34.32 Malignant neoplasm of lower lobe, left bronchus or lung C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung C34.91 Malignant neoplasm of unspecified part of right bronchus or lung C34.92 Malignant neoplasm of unspecified part of left bronchus or lung C78.00 Secondary malignant neoplasm of unspecified lung C78.01 Secondary malignant neoplasm of right lung C78.02 Secondary malignant neoplasm of left lung C78.30 Secondary malignant neoplasm of unspecified respiratory organ C78.39 Secondary malignant neoplasm of other respiratory organs
    [Show full text]
  • A Breathless Builder
    case presentations no03.qxd 17/05/2007 15:38 Page 2 CASE PRESENTATION A breathless builder J.J. Lyons1 P.J. Sime1 Case report hand-grinder, a common task known as "tuck- D. Ward2 The patient was a 30-year-old male mason whose pointing" (figure 2), while intermittently using a T. Watson3 work frequently involved cutting and grinding disposable particle mask. After completing this J.L. Abraham4 brick and cement with powered tools. He was an job, he felt well for ~2 months and then gradu- R. Evans5 active smoker (1–1.5 packs per day). He had ally began to develop a nonproductive cough, 6 M. Budev worked in building construction since the age of dyspnoea on exertion and an 11 kg weight loss K. Costas3 W.S. Beckett1 14 yrs, as a labourer then as a mason and had without fever. Serial pulmonary function testing been a mason for the previous 13 years. He showed restriction and a marked reduction in dif- reported frequent exposure to cement and brick fusing capacity. Chest computed tomography 1Division of Pulmonary and dust while removing stone floors with a jackham- (CT) showed bilateral diffuse infiltrates. A purified Critical Care Medicine, 2Dept of mer. From 8–2 months prior to presentation, he protein derivative test was negative. Anesthesiology and Biomedical had been employed repairing exterior brick on Bronchoalveolar lavage fluid was mucoid, and 3 Engineering and Division of three large apartment buildings (figure 1). This culture was negative. A transbronchial biopsy Thoracic/Foregut Surgery, University of Rochester, Rochester, required cutting through brick and mortar with a was nondiagnostic and the post-bronchoscopy 4Dept of Pathology, SUNY Upstate powered, high-speed demolition saw and grind- chest film showed a very small right apical pneu- Medical University, Syracuse, ing mortar from between bricks with a powered mothorax.
    [Show full text]
  • Various Types of Pneumoconiosis
    Pneumoconiosis MEANING Pneumoconiosis is a chronic lung disease caused due to the inhalation of various forms of dust particles, particularly in industrial workplaces, for an extended period of time. Hence it is also said to be an occupational lung disease, which are a particular subdivision of occupational related diseases that are related primarily to being exposed to harmful substances, whether they are gas or dusts, in the work place, and the pulmonary disorders that may result from it. The severity and type of pneumoconiosis depends on what the dust particles comprise of; for example, small amounts of certain substances, such as asbestos and silica, can lead to serious reactions, while others may not be as harmfulCoalworker's pneumoconiosis Various Types of Pneumoconiosis • The most common types of pneumoconiosis are: • coal workers’ pneumoconiosis, silicosis, • asbestosis. As is evident by their names, these pneumoconioses are caused due to the inhalation of coal mine dust, silica dust, and asbestos fibers. Usually, it takes several years for these pneumoconioses to develop and manifest themselves. However, sometimes, particularly with silicosis, it can develop quite rapidly, within a short period of being exposed to large amounts of silica dust. In their severe form, pneumoconioses often result in the impairment of the lungs, disability, and even untimely death. Asbestosis: This is caused due to the inhalation of fibrous minerals that asbestos is made of. The exposure begins with the baggers, who handle the asbestos by collecting them and packaging them, to workers that make products out of them such as insulation material, cement, and tiles, and people working in the shipbuilding industry, and construction workers.
    [Show full text]
  • A ABPA, 69, 71 Acinus-Terminal Respiratory Unit, 8 Acute
    Index A — in microscopic polyangiitis, 143 — asbestosis, 99 ABPA, 69, 71 — p-ANCA, 143, 144, 147, 148 — BOOP, 57, 59 Acinus-terminal respiratory unit, 8 —— in Wegener granulomatosis, 135, 136, 139 — cell profiles, 16 Acute hypersensitive pneumonitis, ground- Anti Scl-70 antibodies, 113, 115 — CEP, 72 glass attenuation, 22 Anti-GBM disease see Goodpasture disease — Crohn disease, 196 Acute interstitial pneumonia (AIP), 4, 37, Anti-GMB antibodies, 135 — CSS, 147, 150 61–63 Anti–GM-CSF autoantibodies, 167 — DIP, 47 — clinical conditions associated, 62 Antimoniosis, 101 — drug-induced lung diseases, 75, 77 — diagnosis procedure, 61, 63 Anti-neutrophil cytoplasmic autoantibodies — hypersensitivity pneumonitis, 95 — histopathological findings, 61, 62 see ANCAs — idiopathic pulmonary fibrosis, 43 — lung lavage cell profiles, 16 Anti-nuclear antibodies (ANA), in SLE, 119, — in IIP diagnosis, 38–39 — pathogenesis, 61 120, 121 — IPF, 43 — symptoms, 61 Antiphospholipid syndrome, 123 — IPH, 159, 162 — therapy, 63 ARDS see acute respiratory distress syndrome — Langerhans cell histiocytosis, 177 Acute lupus pneumonitis, 119 Asbestosis, 97, 99 — LIP, 65 Acute respiratory distress syndrome (ARDS), — malignant mesothelioma with, 201 — NSIP, 52 in pancreatitis, 193, 194 Asthma, heroin-related, 85 — PAM, 163 Acute silicoproteinosis, 97 — PAP, 167, 168, 169 AIP see acute interstitial pneumonia B — RB-ILD, 47, 49 Airway obstruction, interstitial lung disease BAL see bronchoalveolar lavage — rheumatoid arthritis, 110 and, 12, 15 Ball, R., 107 — Sjögren syndrome,
    [Show full text]